Mga Batayang Estadistika
| LEI | 549300835H8LC7O8VC29 |
| CIK | 1322505 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Albireo Pharma Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2024 |
ALBO / Albireo Pharma Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 10, 2023 |
ALBO / Albireo Pharma Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5*) ALBIREO PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 01345P106 (CUSIP Number) March 31, 2023 (Date of Event Which Requires Filing of this Sta |
|
| March 14, 2023 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33451 Albireo Pharma, Inc. (Exact name of registrant as specified |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 POS AM As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 POS AM As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 2, 2023 Registration Nos. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 POS AM 1 d351738dposam.htm POS AM As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. 333-266893 Registration No. 333-253506 Registration No. 333-241680 Registration No. 333-182877 Registration No. 333-153167 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to Form S-3, Registration Statement No. 333-266893 Po |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 ALBIREO PHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of Incorporation) 001-33451 (Commission File Number) 90 |
|
| March 2, 2023 |
ALBO / Albireo Pharma Inc / ICS OPPORTUNITIES, LTD. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALBIREO PHARMA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 01345P106 (CUSIP Number) FEBRUARY 21, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 2, 2023 Registration Nos. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 2, 2023 Registration Nos. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 2, 2023 Registration Nos. |
|
| March 2, 2023 |
THIRD AMENDED AND RESTATED Certificate OF INCORPORATION ALBIREO PHARMA, Inc. Exhibit 3.1 THIRD AMENDED AND RESTATED Certificate OF INCORPORATION OF ALBIREO PHARMA, Inc. The name of the corporation is Albireo Pharma, Inc. (the “Corporation”). Article 1: The address of the Corporation’s registered office in the state of Delaware is 251 Little Falls Drive, Wilmington, DE 19808, New Castle County. The name of its registered agent at such address is Corporation Service Company. |
|
| March 2, 2023 |
SECOND AMENDED AND RESTATED ALBIREO PHARMA, INC. Article 1: Corporate Offices Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF ALBIREO PHARMA, INC. Article 1: Corporate Offices Section 1.1 Offices. In addition to the corporation’s registered office set forth in the certificate of incorporation, the Board of Directors may at any time establish other offices at any place or places where the corporation is qualified to do business. Article 2: Meetings of Stockholders Section |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 2, 2023 Registration Nos. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ALBIREO PHARMA, INC. (Name of Subject Company) ALBIREO PHARMA, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 01345P106 (CUSIP Numbe |
|
| March 2, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) ALBIREO PHARMA, INC. (Name of Subject Company (Issuer)) ANEMONE ACQUISITION CORP. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Offeror) a wholly owned subsidiary of |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 2, 2023 Registration Nos. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 POS AM As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 2, 2023 Registration Nos. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 POS AM As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 2, 2023 Registration Nos. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 2, 2023 Registration Nos. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 2, 2023 Registration Nos. |
|
| February 27, 2023 |
ALBO / Albireo Pharma Inc / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Albireo Pharma, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 01345P106 (CUSIP Number) February 16, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 24, 2023 |
ALBO / Albireo Pharma Inc / CARLSON CAPITAL L P - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Albireo Pharma, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 01345P106 (CUSIP Number) February 17, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ALBIREO PHARMA, INC. (Name of Subject Company) ALBIREO PHARMA, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 01345P106 (CUSIP Numbe |
|
| February 22, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) ALBIREO PHARMA, INC. |
|
| February 22, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) ALBIREO PHARMA, INC. (Name of Subject Company (Issuer)) ANEMONE ACQUISITION CORP. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Offeror) a wholly owned subsidiary of |
|
| February 22, 2023 |
Press Release issued by Ipsen SA on February 22, 2023 announcing extension of the Offer. EX-99.(a)(5)(B) Exhibit (a)(5)(B) Disclaimer: Intended for international media and investor audiences only Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 • Extension allows for the satisfaction of the HSR Act related condition as outlined in the Merger Agreement • Albireo stockholders are encouraged to tender their shares to the offer today PARIS, FRANCE, 22 |
|
| February 22, 2023 |
Press Release issued by Ipsen SA on February 22, 2023 announcing extension of the Offer. Exhibit (a)(5)(M) Disclaimer: Intended for international media and investor audiences only Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. |
|
| February 14, 2023 |
Exhibit 99.1 FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome ─ Bylvay (odevixibat) granted Priority Review by U.S. FDA ─ ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients ─ Approval in second indication would more than double Bylvay market opportunity BOSTON, MA — February 14, 20 |
|
| February 14, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number |
|
| February 14, 2023 |
ALBO / Albireo Pharma Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 albo282313sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Albireo Pharma, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01345P106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the a |
|
| February 14, 2023 |
ALBO / Albireo Pharma Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
ALBO / Albireo Pharma Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Albireo Pharma, Inc. (Name of Issuer) common stock, $0.01 par value per share (Title of Class of Securities) 01345P 10 6 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 14, 2023 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC |
|
| February 1, 2023 |
ALBO / Albireo Pharma Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) ALBIREO PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 01345P106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this |
|
| January 31, 2023 |
Albireo employee FAQ, dated January 30, 2023 Exhibit (a)(5)(L) TO BE ATTACHED TO AN EMPLOYEE EMAIL AS A PDF, INSERTED IN THE LEADER TOOLKIT AND DISTRIBUTED BROADLY TO EMPLOYEES, AS NECESSARY Questions Regarding Ipsen Acquisition Project Additional Questions - As of January 30, 2023 BEFORE THE CLOSE Q: What is the HR timeline? When are we going to know who is leaving or staying, along with information about retention packages or severance packages? A: As we learn more about the timelines and processes, we intend to share this information and additional details. |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ALBIREO PHARMA, INC. (Name of Subject Company) ALBIREO PHARMA, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 01345P106 (CUSIP Numbe |
|
| January 23, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ALBIREO PHARMA, INC. (Name of Subject Company) ALBIREO PHARMA, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 01345P106 (CUSIP Numbe |
|
| January 23, 2023 |
Employment Agreement, dated as of October 21, 2022, by and between Albireo and Paul D. Streck, M.D. Exhibit (e)(12) EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into effective as of October 21, 2022 (the “Effective Date”) by and between Albireo Pharma, Inc. |
|
| January 23, 2023 |
Exhibit (d)(2)(B) MUTUAL CONFIDENTIALITY AGREEMENT THIS MUTUAL CONFIDENTIALITY AGREEMENT (the “Agreement”) made as of June 10, 2022 (the “Effective Date”), is between Albireo Pharma, Inc. |
|
| January 23, 2023 |
Form of Contingent Value Rights Agreement, by and between Purchaser and the Rights Agent. Exhibit (d)(3) CONTINGENT VALUE RIGHTS AGREEMENT By and between IPSEN BIOPHARMACEUTICALS, INC. |
|
| January 23, 2023 |
Exhibit (a)(1)(E) Offer to Purchase All Outstanding Shares of Common Stock of ALBIREO PHARMA, INC. |
|
| January 23, 2023 |
Exhibit (b)(1) [CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| January 23, 2023 |
Notice of Guaranteed Delivery. Exhibit (a)(1)(C) Notice of Guaranteed Delivery For Tender of Shares of Common Stock of ALBIREO PHARMA, INC. |
|
| January 23, 2023 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ALBIREO PHARMA, INC. |
|
| January 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) ALBIREO PHARMA, INC. |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ALBIREO PHARMA, INC. (Name of Subject Company (Issuer)) ANEMONE ACQUISITION CORP. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Offeror) a wholly owned subsidiary of IPSEN PHARMA SAS (Offeror) a |
|
| January 23, 2023 |
Offer to Purchase, dated January 23, 2023. Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of ALBIREO PHARMA, INC. |
|
| January 23, 2023 |
Form of Letter of Transmittal. Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of ALBIREO PHARMA, INC. |
|
| January 23, 2023 |
Exhibit (d)(2)(A) MUTUAL CONFIDENTIALITY AGREEMENT THIS MUTUAL CONFIDENTIALITY AGREEMENT (the “Agreement”) made as of January 17, 2022 (the “Effective Date”), is between Albireo Pharma, Inc. |
|
| January 23, 2023 |
Form of Summary Advertisement, published January 23, 2023 in the Wall Street Journal. Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ALBIREO PHARMA, INC. (Name of Subject Company) ALBIREO PHARMA, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 01345P106 (CUSIP Number of Class of Secu |
|
| January 19, 2023 |
Employee Presentation (Exhibit 99.1) Exhibit 99.1 Transaction Update US January 19, 2023 CONFIDENTIAL – FOR INTERNAL USE ONLY ©2023 Albireo Pharma, Inc. All rights reserved 2 Agenda • Transaction Updates • Integration Team • Timeline of Events • Employee Matters CONFIDENTIAL – FOR INTERNAL USE ONLY ©2021 Albireo Pharma, Inc. All rights reserved 3 Integration Team • Integration Team is in the process of being established • Albireo Pro |
|
| January 10, 2023 |
Investor Presentation dated January 9, 2023. Exhibit 99.2 Bring The full potential of our innovative medicines to patients The acquisition of Albireo Build A high-value sustainable pipeline 9 January 2023 Deliver Efficiencies to enable targeted investment & growth Boost Focus. Together. A culture of collaboration For patients & society & excellence 1 Disclaimer & safe harbor − This presentation includes only summary information and does not |
|
| January 10, 2023 |
Joint Press Release dated January 9, 2023. Exhibit 99.1 Disclaimer: Intended for international media and investor audiences only Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases • Transaction focused on Bylvay® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases • Acquisition align |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ALBIREO PHARMA, INC. (Name of Subject Company (Issuer)) ANEMONE ACQUISITION CORP. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Offeror) a wholly owned subsidiary of IPSEN PHARMA SAS (Offeror) a |
|
| January 10, 2023 |
Exhibit 99.3 Company Name: Ipsen SA Company Ticker: IPN FP Equity Date: 2023-01-09 Ipsen to Acquire Albireo Accelerating Growth Call Company Participants • Aymeric Le Chatelier, Executive Vice President, Group Chief Financial Officer • Craig Marks, Vice President, Investor Relations • David Loew, Chief Executive Officer • Howard Mayer, Executive Vice President, Head of Research and Development. Ot |
|
| January 9, 2023 |
Exhibit 99.7 CORPORATE LinkedIn – Use Albireo breaking news visual Today, we announced that Albireo has entered into an agreement to be acquired by Ipsen, a global biopharmaceutical company with a diverse portfolio of transformative medicines across three key areas: oncology, rare disease and neuroscience. Joining forces with Ipsen will enable us to build on our foundation, accelerate the developm |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ALBIREO PHARMA, INC. (Name of Subject Company) ALBIREO PHARMA, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 01345P106 (CUSIP Number of Class of Secu |
|
| January 9, 2023 |
Exhibit 99.3 Subject: Exciting news about Albireo’s next chapter [Dear [Dr. [NAME] / Valued Partner] / INSERT CUSTOMARY GREETING], I wanted to share some exciting news about the future of our company. This morning, we announced that Albireo has entered into an agreement to be acquired by Ipsen, a global biopharmaceutical company with a diverse portfolio of transformative medicines across three key |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2023 ALBIREO PHARMA, INC. |
|
| January 9, 2023 |
EX-99.4 5 tm232677d2ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 Subject: Exciting news about Albireo’s next chapter [Dear Valued Partner / INSERT CUSTOMARY GREETING], I wanted to share some exciting news about the future of our company. This morning, we announced that Albireo has entered into an agreement to be acquired by Ipsen, a global biopharmaceutical company with a diverse portfolio of transformati |
|
| January 9, 2023 |
Exhibit 99.1 Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases January 9, 2023 · Transaction focused on Bylvay® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases · Acquisition aligned with Ipsen’s long-term strategy for expanding the scop |
|
| January 9, 2023 |
EX-99.6 7 tm232677d2ex99-6.htm EXHIBIT 99.6 Exhibit 99.6 Project Carter Physician / HCP Letter Subject: Exciting news about Albireo’s next chapter Dear NAME, I wanted to reach out to you directly to share some exciting news about the future of Albireo. Today, we announced that we have entered into an agreement to be acquired by Ipsen, a global biopharmaceutical company with offices worldwide, incl |
|
| January 9, 2023 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ALBIREO PHARMA, INC. (Name of Subject Company (Issuer)) ANEMONE ACQUISITION CORP. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Offeror) a wholly owned subsidiary of IPSEN PHARMA SAS (Of |
|
| January 9, 2023 |
Exhibit 99.1 From: Ron Cooper To: All Albireo Employees Subject: Albireo’s Next Chapter! Dear A-Team, Today marks the beginning of an exciting new chapter for Albireo! Moments ago, we announced that we have entered into a definitive agreement to be acquired by Ipsen, a global biopharmaceutical company with offices worldwide, including in Cambridge, MA. This all-cash transaction will allow Albireo |
|
| January 9, 2023 |
Exhibit 99.2 TO BE ATTACHED TO THE EMPLOYEE EMAIL AS A PDF, INSERTED IN THE LEADER TOOLKIT AND DISTRIBUTED BROADLY TO EMPLOYEES, AS NECESSARY 1. What was announced? · Albireo announced that we’ve entered into a definitive agreement to be acquired by Ipsen, a global biopharmaceutical company, in an all-cash transaction that will allow us to build on our foundation to accelerate the development of o |
|
| January 9, 2023 |
Exhibit 99.5 Project Carter Payor Letter (Reactive) Subject: Exciting news about Albireo’s next chapter Dear Valued Partner, I wanted to share some exciting news about the future of our company. Today, Albireo has entered into an agreement to be acquired by Ipsen, a global biopharmaceutical company with a diverse portfolio of transformative medicines across three key areas: oncology, rare disease |
|
| January 9, 2023 |
EX-2.1 2 tm232666d1ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER among: IPSEN BIOPHARMACEUTICALS, INC., ANEMONE ACQUISITION CORP., ALBIREO PHARMA, INC. and IPSEN PHARMA SAS, solely for the limited purposes set forth herein Dated as of January 8, 2023 TABLE OF CONTENTS Page Article I THE OFFER 2 Section 1.1 The Offer 2 Section 1.2 Company Actions 5 Article II MERGER |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| December 6, 2022 |
Exhibit 99.1 Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors – Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise – Dr. Paul Streck, former Chief Medical Officer at Arena Pharmaceuticals, brings significant global drug development and c |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| November 8, 2022 |
? Exhibit 10.1 Execution Version ? CERTAIN INFORMATION IDENTIFIED BY ?[***]? HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ? PURCHASE AND SALE AGREEMENT BY AND AMONG ALBIREO PHARMA, INC. AND ALBIREO AB AND SAGARD HEALTHCARE PARTNERS (DELAWARE) LP DATED AS OF SEPTEMBER 22, 2022 ? ? ? ? TABLE O |
|
| November 8, 2022 |
Albireo Reports Q3 2022 Financial Results and Business Update Exhibit 99.1 Albireo Reports Q3 2022 Financial Results and Business Update – Bylvay® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 million – New disease modification and native liver survival data with Bylvay in PFIC patients presented at AASLD – Positive Bylvay Phase 3 ASSERT topline data in ALGS presented at AASLD; submissions on track – Completed enrollment in |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 11, 2022 |
Exhibit 99.2 ?2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only ASSERT Topline Data Results ASSERT: Phase 3 study evaluating the safety and efficacy of Bylvay ? (odevixibat) in patients with Alagille syndrome October 2022 (Nasdaq: ALBO) For Media & Investors Only ?2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 2 Forward Looking Statements This prese |
|
| October 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| October 11, 2022 |
Exhibit 99.1 Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay? (odevixibat) in Alagille Syndrome ? Highly statistically significant improvement in pruritus primary endpoint (p=0.002) ? Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001) ? Substantial improvements in multiple sleep parameters ? Well tolerated with low incidence of drug-related diar |
|
| October 3, 2022 |
ALBO / Albireo Pharma Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 26, 2022 |
ALBO / Albireo Pharma Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 26, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.01 par value per share, of Albireo Pharma, Inc. and further agree to the filing of this Joint Filing Agreement as an exh |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Numbe |
|
| September 22, 2022 |
Albireo Announces $115 Million Royalty Monetization Agreement with Sagard Exhibit 99.1 Albireo Announces $115 Million Royalty Monetization Agreement with Sagard - Upfront payment for continued clinical development and commercialization of Bylvay? - Sagard to receive a mid-single digit average royalty rate on Bylvay sales - No liens against Bylvay intellectual property - Right to buy out Sagard?s investment at any time BOSTON, MA ? September 22, 2022 ? Albireo Pharma, In |
|
| August 25, 2022 |
Albireo Pharma, Inc. Common Stock TABLE OF CONTENTS ? Filed pursuant to Rule 424(b)(3) ?Registration Statement No. 333-266893? PROSPECTUS Albireo Pharma, Inc. $100,000,000 Common Stock We have entered into a Sales Agreement, or sales agreement, with Cowen and Company, LLC, or Cowen, dated August 15, 2022, relating to the sale of shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreem |
|
| August 23, 2022 |
ALBIREO PHARMA, INC. 53 State Street, 19th Floor Boston, Massachusetts 02109 ALBIREO PHARMA, INC. 53 State Street, 19th Floor Boston, Massachusetts 02109 August 23, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell RE: Albireo Pharma, Inc. Registration Statement on Form S-3 Filed August 16, 2022 File No. 333-266893 Acceleration Request Dear Mr. Campbell: With re |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| August 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Albireo Pharma, Inc. |
|
| August 16, 2022 |
As filed with the Securities and Exchange Commission on August 15, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 15, 2022 Registration No. |
|
| August 16, 2022 |
Exhibit 4.7 ALBIREO PHARMA, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04( |
|
| August 16, 2022 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| August 16, 2022 |
Exhibit 1.2 Albireo pharma, Inc. Common Stock (par value $0.01 per share) SALES AGREEMENT August 15, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Albireo Pharma, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1.?????????????Issuance and Sale of Shares. The Compan |
|
| August 16, 2022 |
Form of Subordinated Indenture. Exhibit 4.8 ALBIREO PHARMA, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). |
|
| August 15, 2022 |
Albireo Reports Q2 2022 Financial Results and Business Update Exhibit 99.1 Albireo Reports Q2 2022 Financial Results and Business Update ? Bylvay?(odevixibat) Q2 2022 net product revenue $5.9 million, June YTD 2022 $10.5 million ? Agreed Bylvay reimbursement contract in Italy and Belgium with launches planned for the fall ? Global Phase 3 ASSERT study in Alagille syndrome on track for topline data readout this fall ? Global Phase 3 BOLD study in biliary atre |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2022 |
Nonemployee Director Compensation Policy. Exhibit 10.1 ALBIREO PHARMA, INC. NONEMPLOYEE DIRECTOR COMPENSATION POLICY (Adopted January 23, 2017, Last modified June 15, 2022) The Board of Directors of Albireo Pharma, Inc. (the ?Company?) has approved the following Nonemployee Director Compensation Policy (this ?Policy?) to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company?s Board |
|
| August 10, 2022 |
Exhibit 99.1 Albireo Appoints New Members to Board of Directors ? Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances at Boston Children?s Hospital, bring significant global drug development, financial and commercial operations expertise to Albireo BOSTON, MA ? Aug 10, 2022 ? Albireo Pharma, Inc. (Nasdaq: ALBO), |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 9 |
|
| July 29, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 90 |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 90 |
|
| May 16, 2022 |
Albireo Reports Q1 2022 Financial Results and Business Update Exhibit 99.1 Albireo Reports Q1 2022 Financial Results and Business Update ? Positive BylvayTM (odevixibat) global commercial launch in U.S., Germany and United Kingdom with Q1 2022 product revenue, net $4.7 million ? Phase 3 ASSERT study in Alagille syndrome fully enrolled, patient numbers above original target and on track for topline data readout in 2022 ? Phase 3 BOLD study in biliary atresia |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 90- |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??????) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| April 21, 2022 |
DEF 14A 1 tm223503-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 1, 2022 |
Exhibit 10.34.4 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this ?Third Amendment?), dated as of June 30, 2021, is entered into by and between NS Boston III PO Owner LLC, a Delaware limited liability company (?Landlord?) and Albireo Pharma, Inc., a Delaware corporation (?Tenant?). WITNESSETH WHEREAS, Landlord and Tenant are the current parties to that certain Office Lease Agreement dat |
|
| March 1, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Albireo Pharma, Inc. |
|
| March 1, 2022 |
Restated Certificate of Incorporation, as amended, of the Registrant. Exhibit 3.1 ? SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIODEL INC. The undersigned, Solomon S. Steiner, Ph.D., in accordance with the provisions of Sections 242 and 245 of the Delaware General Corporation Law (?DGCL?) hereby certifies that: 1. He is the duly elected and acting Chairman of the Board, President and Chief Executive Officer of Biodel Inc., a Delaware corporation (th |
|
| March 1, 2022 |
Description of the Registrant’s Securities. Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Albireo Pharma, Inc. (the ?Company? or ?we?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.01 per share. DESCRIPTION OF COMMON STOCK We are authorized to issue 60,000, |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 1, 2022 |
Sublease Agreement, dated as of December 6, 2021, by and between the Registrant and Hi Marley, Inc. Exhibit 10.35 SUBLEASE This Sublease (?Sublease?) is made as of December 6, 2021, by and between Albireo Pharma, Inc. a Delaware corporation having an address of 10 Post Office Square, Boston, Massachusetts 02109 (?Sublandlord?), and Hi Marley, Inc., a Delaware corporation having an address of 77 Franklin St 9th Floor, Boston, Massachusetts 02110 (?Subtenant?). WITNESSETH WHEREAS, reference is mad |
|
| March 1, 2022 |
Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update Exhibit 99.1 Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update ? BylvayTM (odevixibat) launched in the U.S. and Europe, 2021 product revenue, net $7 million ? NICE endorses clinical and economic benefits of Bylvay ? Phase 3 study in Alagille syndrome on track for readout in 2022 ? Reports $248.1 million of cash and cash equivalents, sufficient to fund operations into 2024 |
|
| March 1, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 ? Subsidiaries of the Registrant ? Albireo AB, a limited liability company registered in Sweden Elobix AB, a limited liability company registered in Sweden Albireo Pharma Limited, a limited liability company registered in UK Albireo Pharma Security Corporation, a Massachusetts corporation |
|
| March 1, 2022 |
Albireo Pharma, Inc. Corporate Code of Conduct and Ethics and Whistleblower Policy. Exhibit 14.1 ALBIREO PHARMA, INC. CORPORATE CODE OF CONDUCT AND ETHICS AND WHISTLEBLOWER POLICY Effective October 25, 2016 INTRODUCTION Albireo Pharma, Inc. (?we? or the ?Company? and, together with our direct and indirect subsidiaries, ?Albireo?) has adopted this Corporate Code of Conduct and Ethics and Whistleblower Policy (the ?Code?) to provide our associates, as defined below, with a clear un |
|
| March 1, 2022 |
Exhibit 10.36 SUBLEASE AGREEMENT This SUBLEASE AGREEMENT, dated as of this 7th day of December, 2021, is made by and between INSTITUTE FOR HEALTHCARE IMPROVEMENT, a Michigan corporation (?Sublandlord?), and ALBIREO PHARMA, Inc., a Delaware corporation (?Subtenant?). RECITALS: A.Sublandlord, as tenant, leases the Master Lease Premises from Master Landlord under the Master Lease for the Master Lease |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 90 |
|
| February 14, 2022 |
ALBO / Albireo Pharma Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Albireo Pharma, Inc. (Name of Issuer) common stock, $0.01 par value per share (Title of Class of Securities) 01345P 10 6 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2022 |
ALBO / Albireo Pharma Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) ALBIREO PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 01345P106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this |
|
| February 14, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| January 5, 2022 |
Exhibit 99.1 Albireo Increases 2021 BylvayTM (odevixibat) Sales Guidance ? Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M ? Unaudited cash of $254M, updates guidance with cash into 2024 ? BOLD Phase 3 study in biliary atresia is over 50% enrolled ? ASSERT Phase 3 study in Alagille syndrome on track for topline data by end of year BOSTON ? January 5, 2022 ? Albireo Pharma, Inc |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Comm |
|
| January 5, 2022 |
Exhibit 99.1 Albireo Increases 2021 BylvayTM (odevixibat) Sales Guidance ? Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M ? Unaudited cash of at least $248M, updates guidance with cash into 2024 ? BOLD Phase 3 study in biliary atresia is over 50% enrolled ? ASSERT Phase 3 study in Alagille syndrome on track for topline data by end of year BOSTON ? January 5, 2022 ? Albireo Ph |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| December 9, 2021 |
Albireo Announces Changes to R&D Organization Exhibit 99.1 Albireo Announces Changes to R&D Organization BOSTON, MA ? December 9, 2021 ? Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year after almost three and a half years with the Company. Jan Mattsson, Ph.D. |
|
| November 4, 2021 |
Albireo Pharma, Inc. Incentive Compensation Recoupment Policy Exhibit 10.2 ALBIREO PHARMA, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY Albireo Pharma, Inc. has adopted this Incentive Compensation Recoupment Policy, which is effective as of November 3, 2021 (the ?Effective Date?). 1.Certain Definitions. (a)?Board? means the Board of Directors of the Company. (b)?Committee? means the Compensation Committee of the Board. (c)?Company? means Albireo Pharma, Inc |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 4, 2021 |
Exhibit 99.1 Albireo Reports Q3 Financial Results and Business Update ? BylvayTM (odevixibat) approved in the U.S. and Europe, partial Q3 ?21 revenue of $1.1 million? ? ASSERT & BOLD Phase 3 studies enrolling, on track for topline data readouts ? ? 12 abstracts accepted at AASLD & NASPGHAN scientific congresses ? ? A3907 Phase 1 topline data expected in Q4?21, A2342 composition of matter allowed ? |
|
| November 4, 2021 |
EXECUTION VERSION ? Exhibit 10.1 ASSET PURCHASE AGREEMENT BY AND AMONG ALBIREO AB, ALBIREO PHARMA, INC. AND ARES TRADING SA August 31, 2021 ? ? [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ? TABLE OF CONTENTS ? ? ? ? ? Page ARTICLE |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| September 7, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| September 7, 2021 |
Exhibit 99.1 Albireo Sells Priority Review Voucher (PRV) for $105 Million ? PRV was granted to Albireo with the FDA approval of BylvayTM (odevixibat) in July ? ? Non-dilutive capital further strengthens the Company?s financial position ? BOSTON, MA ? September 7, 2021 ? Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announce |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2021 |
Exhibit 99.1 Albireo Reports Q2 Financial Results and Business Update ? BylvayTM (odevixibat) approved in U.S. & EU as only once-daily drug indicated for patients with PFIC ? ? Commercialization underway with Bylvay, first prescriptions received in the U.S. ? ? German price listing expected in September ? ? Company to host a conference call and webcast today at 10:00 a.m. ET ? BOSTON, MA ? August |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 9 |
|
| July 21, 2021 |
Exhibit 99.2 Albireo Announces FDA Approval of Bylvay? (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) ? Only once-daily drug indicated for the treatment of pruritus in PFIC ? ? Commercial launch of Bylvay immediate; available for prescription in the coming days ? ? Rare Pediatric Disease Priority Review Voucher issued to Albireo by the |
|
| July 21, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 90 |
|
| July 21, 2021 |
Exhibit 99.1 Albireo Receives European Marketing Authorization of Bylvay? (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC) ? First approval in the world of Bylvay for the treatment of PFIC ? ? Only once-daily drug indicated to treat all forms of PFIC ? ? European Commission (EC) decision based on data from the largest Phase 3 PFIC trial to date ? ? Ge |
|
| June 21, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ALBIREO PHARMA, INC. It is hereby certified that: FIRST: The name of the corporation is Albireo Pharma, Inc. (the ?Corporation?). SECOND: The Restated Certificate of Incorporation of the Corporation, filed on May 17, 2007, as amended (the ?Restated Certificate of Incorporation?), is hereby further amended by deleting the first |
|
| June 21, 2021 |
Albireo Pharma, Inc. 2018 Equity Incentive Plan, as amended. Exhibit 10.1 ALBIREO PHARMA, INC. 2018 EQUITY INCENTIVE PLAN, AS AMENDED 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Albireo Pharma, Inc. 2018 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 90 |
|
| May 6, 2021 |
Exhibit 99.1 Albireo Reports Q1 Financial Results and Business Update ? BylvayTM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU? ? Completed global commercial agreements for two key top ten markets ? ? ASSERT & BOLD Phase 3 studies enrolling and on track ? ? Advanced novel MOA ASBTi A3907 into Phase 1 study ? ? Recent CTO appointment strengthens leadership t |
|
| May 6, 2021 |
Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 90-0 |
|
| May 6, 2021 |
Nonemployee Director Compensation Policy. ? Exhibit 10.1 ALBIREO PHARMA, INC. NONEMPLOYEE DIRECTOR COMPENSATION POLICY (Adopted January 23, 2017, Last modified March 4, 2021) The Board of Directors of Albireo Pharma, Inc. (the ?Company?) has approved the following Nonemployee Director Compensation Policy (this ?Policy?) to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company?s Boa |
|
| April 27, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 16, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by |
|
| February 25, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number |
|
| February 25, 2021 |
As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number |
|
| February 25, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
Exhibit 4.7 ALBIREO PHARMA, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04( |
|
| February 25, 2021 |
Exhibit 99.1 Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update – NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch – – Announces odevixibat co-promotion agreement with Travere, a leading rare disease company – – ASSERT global pivotal Phase 3 trial in Alagille syndrome initiated and enrolling – – BOLD global pivotal Phase 3 study in biliary atresia |
|
| February 25, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 ? Subsidiaries of the Registrant ? Albireo AB, a limited liability company registered in Sweden Elobix AB, a limited liability company registered in Sweden Albireo Security Corp., a Massachusetts security corporation Albireo Pharma Security Corporation, a Massachusetts corporation |
|
| February 25, 2021 |
Albireo Pharma, Inc. Corporate Code of Conduct and Ethics and Whistleblower Policy. Exhibit 14.1 ALBIREO PHARMA, INC. CORPORATE CODE OF CONDUCT AND ETHICS AND WHISTLEBLOWER POLICY Effective October 25, 2016 Last updated August 12, 2020 INTRODUCTION Albireo Pharma, Inc. (?we? or the ?Company? and, together with our direct and indirect subsidiaries, ?Albireo?) has adopted this Corporate Code of Conduct and Ethics and Whistleblower Policy (the ?Code?) to provide our associates, as d |
|
| February 25, 2021 |
EX-1.2 2 tm217904d2ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 Execution Copy Albireo pharma, Inc. Common Stock (par value $0.01 per share) SALES AGREEMENT February 25, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Albireo Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follo |
|
| February 25, 2021 |
Exhibit 10.1 Execution Copy Albireo pharma, Inc. Common Stock (par value $0.01 per share) SALES AGREEMENT February 25, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Albireo Pharma, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The |
|
| February 25, 2021 |
Form of Subordinated Indenture. EX-4.8 4 tm217904d2ex4-8.htm EXHIBIT 4.8 Exhibit 4.8 ALBIREO PHARMA, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c |
|
| February 25, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
Amendment No.4 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Albireo Pharma, Inc. (Name of Issuer) common stock, $0.01 par value per share (Title of Class of Securities) 01345P 10 6 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 16, 2021 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERCEPTIVE ADVISORS LLC |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Albireo Pharma, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01345P106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) ALBIREO PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 01345P106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this |
|
| February 11, 2021 |
©2021 Albireo Pharma, Inc. All rights reserved Commercial Day: Road to $1 Billion February 11, 2021 Exhibit 99.1 ©2021 Albireo Pharma, Inc. All rights reserved Commercial Day: Road to $1 Billion February 11, 2021 2 ©2021 Albireo Pharma, Inc. All rights reserved Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include statements, other than statements of hist |
|
| February 11, 2021 |
Exhibit 99.2 Albireo Presents Odevixibat Commercialization Road to $1 Billion – Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU launch, with focus on market access – – Expansion opportunity beyond PFIC and beyond odevixibat – – Commercial management to host conference call and webcast today at 11:30 a.m. EST– BOST |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number |
|
| January 25, 2021 |
Exhibit 99.1 Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat - Company receives FDA Priority Review with PDUFA date set for July 20, 2021 - - Submission data for PFIC types 1, 2, 3, supporting once-daily use across a wide range of patients - - FDA has granted odevixibat Fast Track, Rare Pediatric Disease and Orphan Drug Designations - - Odevixibat on track to be first |
|
| January 25, 2021 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| December 8, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| December 8, 2020 |
Exhibit 99.1 Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC - Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients - - EMA grants accelerated assessment, validates Marketing Authorization Application for odevixibat with orphan designation and access to PRIority MEdicines (PRIME) - - FDA has granted odevixibat Fast Track, Rare |
|
| November 13, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number |
|
| November 13, 2020 |
Exhibit 99.1 New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease - PEDFIC 1 meets both U.S. and EU primary and secondary endpoints with highly statistically significant reductions in serum bile acids and pruritus - - Interim results from long-term extension study show sustained improvements in serum bile acids, pruritus - - Improvements in growth measure |
|
| November 5, 2020 |
Form of Restricted Stock Unit Agreement under the 2020 Inducement Equity Incentive Plan. Exhibit 10.3 Form of RSU Agreement Restricted Stock Unit No. [] ALBIREO PHARMA, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Grant under the Company’s 2020 Inducement Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Restricte |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| November 5, 2020 |
Albireo Pharma, Inc. 2020 Inducement Equity Incentive Plan. Exhibit 10.1 2020 Inducement Equity Incentive Plan 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Albireo Pharma, Inc. 2020 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the term Ad |
|
| November 5, 2020 |
Form of Stock Option Agreement under the Albireo Pharma, Inc. 2020 Inducement Equity Incentive Plan. Exhibit 10.2 Form of Stock Option Agreement Option No. ALBIREO PHARMA, INC. Stock Option Grant Notice Non-Qualified Stock Option Grant under the Company’s 2020 Inducement Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Maximum Number of Shares for which this Option is exercisable: 4. Exercise (purchase) price per share: 5. Option Expiration Date: 6. Vesting St |
|
| November 5, 2020 |
Exhibit 99.1 Albireo Reports Q3 2020 Financial Results and Provides Business Update - Positive Phase 3 data for odevixibat in PFIC with filings on track for no later than early 2021 - - Phase 3 PFIC data accepted as late breakers at upcoming AASLD Meeting - - Introduces new and novel bile acid modulator A3907 at AASLD - - Raised $160 million in gross proceeds in public offering of 4,000,000 shares |
|
| October 23, 2020 |
Amendment No. 1 to Schedule 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Albireo Pharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 01345P 106 (CUSIP Number) Stefan Fischer TVM Capital Ottostrasse 4 80333 Munich, Germany (49) 89998992-48 (Name, Address and Telephone |
|
| October 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| September 10, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424B5 Registration No. |
|
| September 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number |
|
| September 10, 2020 |
Exhibit 1.1 Execution Version 4,000,000 SHARES ALBIREO PHARMA, INC. COMMON STOCK UNDERWRITING AGREEMENT September 9, 2020 Cowen and Company, LLC William Blair & Company, L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o William Blair & Company, L.L.C. 150 N. Riverside Plaza Chicago, Illinois 60606 Dear Ladies and Gent |
|
| September 10, 2020 |
Albireo Prices Public Offering of 4,000,000 Shares of Common Stock Exhibit 99.1 Albireo Prices Public Offering of 4,000,000 Shares of Common Stock BOSTON, September 9, 2020 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $40.00 |
|
| September 9, 2020 |
Termination of a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number |
|
| September 8, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number |
|
| September 8, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number |
|
| September 8, 2020 |
Exhibit 99.1 Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC - Highly statistically significant reductions in both pruritus and serum bile acids- -Well tolerated with very low incidence of diarrhea- -Similar efficacy in children with PFIC1 or PFIC2- -Pivotal trial results substantiate potential for odevixibat to be first drug for PFIC patients- -Regulatory submissions for |
|
| September 8, 2020 |
Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stock Exhibit 99.1 Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stock BOSTON, September 8, 2020 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of 3,000,000 shares of its common stock. In connection with the offeri |
|
| September 8, 2020 |
Subject to Completion, Dated September 8, 2020 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424B5 Registration No. |
|
| September 8, 2020 |
Exhibit 99.2 PROSPECTUS SUPPLEMENT SUMMARY Overview We are a biopharmaceutical company focused on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases (GI) and disorders. We are pursuing the development of our lead product candidate, odevixibat (formerly known as A4250), for patients with progressi |
|
| August 18, 2020 |
Exhibit 99.1 Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH ‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒ BOSTON — August 18, 2020 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced topline res |
|
| August 18, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| August 14, 2020 |
ALBIREO PHARMA, INC. 10 Post Office Square, Suite 1000 Boston, Massachusetts 02109 August 14, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento RE: Albireo Pharma, Inc. Registration Statement on Form S-3 Filed August 6, 2020 File No. 333-241680 Acceleration Request Dear Ms. Sarmento: |
|
| August 6, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 6, 2020 Registration No. |
|
| August 6, 2020 |
Table of Contents Stock UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 9 |
|
| August 6, 2020 |
Albireo Reports Q2 2020 Financial Results and Provides Business Update Exhibit 99.1 Albireo Reports Q2 2020 Financial Results and Provides Business Update — Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials — — Enrolled first biliary atresia patients in second odevixibat pivotal study — — Completed two financing transactions to secure cash into beginning of 2022 — — Management to host conference call and webcast today at 10:00 a.m. ET — BOSTON, MA |
|
| June 15, 2020 |
Submission of Matters to a Vote of Security Holders 8-K 1 a20-2210628k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 |
|
| June 9, 2020 |
EX-10.3 4 tm2022106d1ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. AMENDMENT TO ROYALTY INTEREST ACQUISITION AGREEMENT AMENDMENT, dated as of June 8, |
|
| June 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33451 90-0136863 (State or other jurisdiction of incorporation) (Commission File |
|
| June 9, 2020 |
Exhibit 99.1 Albireo Announces Two Financing Transactions to Extend Cash Runway into the beginning of 2022 — Restructured HealthCare Royalty Partners elobixibat royalty monetization agreement nets additional $15M in non-dilutive capital — — Initial draw down of $10M on debt facility of up to $80M with Hercules Capital — BOSTON — June 9, 2020 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage |
|
| June 9, 2020 |
Form of Warrant issued by the Registrant to Hercules Capital, Inc. Exhibit 10.2 NEITHER THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE, AND, ACCORDINGLY, MAY NOT BE OFFERED FOR SALE OR SOLD, PLEDGED OR HYPOTHECATED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) |
|
| June 9, 2020 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of June 8, 2020 and is entered into among ALBIREO PHARMA, INC., a Delaware corporation (the “Parent”), ALBIREO AB, a company duly incorporated under the laws of Sweden (Registration Number 556737-4631) and a wholly-owned Subsidiary of the Parent (“Albireo AB” and, together with the Parent and any other P |
|
| May 27, 2020 |
Albireo Pharma, Inc. Common Stock Use these links to rapidly review the document TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. |
|
| May 14, 2020 |
ALBIREO PHARMA, INC. 10 Post Office Square, Suite 1000 Boston, Massachusetts 02109 May 14, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller RE: Albireo Pharma, Inc. Registration Statement on Form S-3 Filed May 7, 2020 File No. 333-238063 Acceleration Request Dear Mr. Buchmiller: With |
|
| May 7, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on May 7, 2020 Registration No. |
|
| May 7, 2020 |
Form of Subordinated Indenture. Exhibit 4.8 ALBIREO PHARMA, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). |
|
| May 7, 2020 |
Exhibit 4.7 ALBIREO PHARMA, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04( |
|
| May 7, 2020 |
Albireo Reports Q1 2020 Financial Results and Provides Business Update EX-99.1 2 tm2018672d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Albireo Reports Q1 2020 Financial Results and Provides Business Update — Commercial preparations advancing, with topline PEDFIC 1 results expected mid-2020 — — First sites initiated for second pivotal trial in biliary atresia — — Management to host conference call and webcast today at 10:00 a.m. ET — BOSTON, MA — May 7, 2020 — Albireo Pharm |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 90-0 |
|
| May 7, 2020 |
Sales Agreement, dated as of May 7, 2020, by and between the Registrant and Cowen and Company, LLC Exhibit 1.2 Execution Version ALBIREO PHARMA, INC. COMMON STOCK (par value $0.01 per share) SALES AGREEMENT May 7, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Albireo Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Comp |
|
| May 7, 2020 |
Stock UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001‑33451 Albi |
|
| May 7, 2020 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 90-0 |
|
| May 7, 2020 |
Second Amendment to lease THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”), dated as of May 4, 2020, is entered into by and between NS Boston III PO Owner LLC, a Delaware limited liability company (“Landlord”) and Albireo Pharma, Inc. |
|
| May 7, 2020 |
Nonemployee Director Compensation Policy. ALBIREO PHARMA, INC. NONEMPLOYEE DIRECTOR COMPENSATION POLICY (Adopted January 23, 2017, Last modified March 6, 2020) The Board of Directors of Albireo Pharma, Inc. (the “Company”) has approved the following Nonemployee Director Compensation Policy (this “Policy”) to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Directors |
|
| April 17, 2020 |
BIOD / Biodel, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 17, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 26, 2020 |
ALBIREO STATEMENT ON THE COVID-19 CRISIS, AND IMPACT ON OUR BUSINESS March 26, 2020 Exhibit 99.1 ALBIREO STATEMENT ON THE COVID-19 CRISIS, AND IMPACT ON OUR BUSINESS March 26, 2020 Our top priority is the safety of our employees. We also remain fully committed to the patients we serve and are grateful that our ongoing trials are fully enrolled and there are sufficient clinical trial supplies to conduct those trials. As with others, the current crisis is disruptive to our business |
|
| March 26, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33451 90-0136863 (State or other jurisdiction of (Commission File (IRS Employer |
|
| March 2, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) 90 |
|
| March 2, 2020 |
Description of the Registrant’s Securities. Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Albireo Pharma, Inc. (the “Company” or “we”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.01 per share. DESCRIPTION OF COMMON STOCK We are authorized to issue 30,000, |
|
| March 2, 2020 |
Exhibit 99.1 Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provides Business Update March 2, 2020 — Phase 3 odevixibat PFIC trial fully enrolled — — Initiating pivotal trials in biliary atresia first half of 2020 and Alagille syndrome by year end— — Management to host conference call and webcast today at 10:00 a.m. ET — BOSTON, March 02, 2020 (GLOBE NEWSWIRE) - Albireo Ph |
|
| March 2, 2020 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Albireo Limited, a limited company registered in England and Wales Albireo, Inc., a Delaware corporation Albireo AB, a limited liability company registered in Sweden Elobix AB, a limited liability company registered in Sweden Albireo Security Corp., a Massachusetts security corporation Albireo Pharma Security Corporation, a Massachusetts corporation |
|
| March 2, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001‑334 |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
BIOD / Biodel, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) ALBIREO PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 01345P106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this |
|
| February 14, 2020 |
BIOD / Biodel, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO.3 TO SCHEDULE 13G Passive Investment Amendment No.3 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Albireo Pharma, Inc. (Name of Issuer) common stock, $0.01 par value per share (Title of Class of Securities) 01345P 10 6 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 14, 2020 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2020 PERCEPTIVE ADVISORS LLC |
|
| February 12, 2020 |
BIOD / Biodel, Inc. / Satter Muneer A - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Albireo Pharma, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01345P106 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 3, 2020 |
Exhibit 99.1 Albireo Announces Closing of $46 Million Public Offering Including Exercise in Full of Underwriters’ Option to Purchase Additional Shares BOSTON, Feb. 3, 2020 (GLOBE NEWSWIRE) - Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten public |
|
| February 3, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| January 30, 2020 |
Albireo Prices $40 Million Public Offering of Common Stock Exhibit 99.1 Albireo Prices $40 Million Public Offering of Common Stock BOSTON — January 29, 2020 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per shar |
|
| January 30, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| January 30, 2020 |
Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| January 30, 2020 |
Underwriting Agreement, dated January 29, 2020, by and between the Company and Jefferies LLC. Exhibit 1.1 1,905,000 SHARES OF COMMON STOCK ALBIREO PHARMA, INC. UNDERWRITING AGREEMENT January 29, 2020 JEFFERIES LLC As Representative of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Albireo Pharma, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A |
|
| January 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| January 29, 2020 |
Exhibit 99.1 Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases — Reiterates Top Line Data on Phase 3 in PFIC Expected Mid-2020 — — To Initiate Pivotal Trials in Biliary Atresia and Alagille Syndrome in 2020 — BOSTON, MA — January 29, 2020 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulator |
|
| January 29, 2020 |
Exhibit 99.2 PROSPECTUS SUPPLEMENT SUMMARY Overview We are a biopharmaceutical company focused on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The initial target indication for our lead product candidate, odevixibat (formerly known as A4250), is progressive familial intrahepa |
|
| January 29, 2020 |
Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| January 29, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 ALBIREO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33451 (Commission File Number) |
|
| January 29, 2020 |
Albireo Announces Proposed Public Offering of Common Stock Exhibit 99.1 Albireo Announces Proposed Public Offering of Common Stock BOSTON — January 29, 2020 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with the offering, Albireo intends to grant the underwr |
|
| November 6, 2019 |
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into effective as of October 31, 2019 (the “Effective Date”) by and between Albireo Pharma, Inc. |
|
| November 6, 2019 |
Stock UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001‑33451 |
